Abstract A008: Better outcomes for ovarian cancer associated with the detection of anti-EBV TCR CDR3s: Potential relevance to diffuse large B-cell lymphoma

Abstract Given the ongoing challenges regarding the specific roles of viral infections in cancer etiology, or as cancer co-morbidities, this study assessed potential associations between anti-viral, T-cell receptor (TCR) complementarity domain region-3 (CDR3s) and clinical outcomes for ovarian cancer. Analyses revealed that patients with exact matches of anti-Epstein-Barr virus (EBV) CDR3 amino acid sequences exhibited better outcomes for both overall and disease-specific survival. However, better outcomes were not observed when assessing anti-viral CDR3s representing cytomegalovirus, influenza A, or Sars-CoV-2. Due to previous occurrences of the occasional misdiagnoses of lymphoma as ovarian cancer, the frequency of anti-EBV CDR3s in lymphoma patients was determined. These frequencies were relatively high, particularly in diffuse large B-cell lymphoma. These findings (i) underscore the potential value of anti-EBV immune responses in terms of patient outcomes; (ii) raise questions about the potential value of anti-EBV immunotherapies; and (iii) support further inquiry into the relationship between EBV infection and previously reported cases of ovary-resident lymphoma. Citation Format: Nandini Goel, Madeline C Baker, George Blanck, Rahul Jain, Michael J Diaz, Taha I Huda, Andrea Chobrutskiy, Boris I Chobrutskiy, Joanna J Song, Veda Naga Priya Vangala. Better outcomes for ovarian cancer associated with the detection of anti-EBV TCR CDR3s: Potential relevance to diffuse large B-cell lymphoma [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl):Abstract nr A008.